Tag Archives: diagnostics

Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

28 Jun

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: USA-Based Venture Capital Firm Invests in Medical Devices, Diagnostics, and Digital Health with Strong Interests in Applications of AI and Machine Learning

28 Jun

A venture capital company founded in 2005 and located in California manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

14 Jun

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Venture Firm Seeking Cellular Engineering Technologies for Diagnostics, Devices, and Therapeutics

10 May

A venture fund focusing on the frontiers of the intersection of science and technology looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Toronto-Based Single Family Office Looking to Invest in Seed-Stage Medtech, Diagnostics, and Digital Health Companies

3 May

A single family office based in Toronto, Ontario has its main focus on real estate and mining, but is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space. The firm may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA VC Firm Seeks to Invest in All Sectors of Life Sciences, with Focus on Companies Outside of Major Biotech Hubs

3 May

A venture capital firm based in Texas is focused on early and growth-stage biotech and medical device companies. The group is currently raising their second fund and is actively evaluating deals. Initial investments typically are in the $3M-$5M range and are usually in the form of straight equity, but may use convertible notes in select situations. The firm looks to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space and will consider medtech companies on a secondary basis. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area, however the group prioritizes companies with products addressing unmet medical need and unique mechanisms of action. For early-stage companies, the firm targets companies who have at least had a pre-IND meeting with the FDA and invest in companies ranging from pre-clinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: